AEON
AEON Biopharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
AEON Profile
Aeon Biopharma, Inc.
A biopharmaceutical company, develops botulinum toxins for the treatment of debilitating medical conditions
Pharmaceutical
Invalid Date
07/24/2023
American Stock Exchange
5
12-31
Common stock
5 Park Plaza, Suite 1750, Irvine, California 92614
--
AEON Biopharma, Inc., was incorporated in Delaware in February 2012. The Company is a clinical-stage biopharmaceutical company focused on the development of the proprietary botulinum toxin complex ABP-450 for debilitating medical conditions, with an initial focus on the neuroscience market. The company has completed a Phase 2 study of ABP-450 for cervical dystonia and is conducting a Phase 2 study of ABP-450 for chronic and episodic migraine. Top-line data from the episodic migraine cohort of the Phase 2 study was reported in October 2023, and the chronic migraine cohort is still in progress. ABP-450 is a botulinum toxin conjugate currently approved and marketed by Evolus under the name jeuveau for cosmetic indications. ABP-450 is manufactured by Daewoong in cGMP in facilities approved by the FDA, Health Canada and EMA. The company has exclusive development and distribution rights for ABP-450 therapeutic indications in the US, Canada, the EU, the UK and certain international regions. The company has built an experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization.